Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after antologous bone marrow transplantation

European Cytokine Network

Volumn 8, Issue 4, 1997, Pages 389-394

  Vey, Norbert ^a   Viens, Patrice ^a   Fossat, Chantai ^b   Olive, Daniel ^a   Sainty, Danielle ^a   Baume, Daniel ^a   Stoppa, Anne Marie ^a   Bouabdallah, Réda ^a   Brandely, Maud ^c   Gastaut, Jean Albert ^a   Maraninchi, Dominique ^a   Blaise, Didier ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b TIMONE HOSPITAL   (France)

^c SANOFI   (France)

Author keywords

Autologous bone marrow transplantation; Gamma interferon; Hematologic malignancies; Immunotherapy; Interleukin 2; Solid tumor

Indexed keywords

RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; ASTHENIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CHEMOTAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPENIA; FEMALE; FEVER; GRANULOCYTE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOMA; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUTROPENIA; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTES; HUMANS; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 6844239545     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Rosenberg S A, Lotze M T, Muul L M, Chang A E, Avis F P, Leitman S, Linehan W M, Robertson C N, Lee R E, Rubin J T, Seipp C, Simpson C, White D. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med. 316: 889.
2. Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa A M, Reiffers J, Gratecos N, Bertau-Perez P, Mannoni P, Mawas C, Hercend T, Sebahoun G, Carcassonne Y. 1991. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78: 2182.
3. Gisselbrecht C, Maraninchi D, Pico J L, Milpied N, Coiffier B, Divine M, Tiberghien P, Bosly A, Tilly H, Boulat O, Brandely M. 1994. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 83: 2081.
4. Henney C S, Kuribayashi K, Kern D E. 1981. Interleukin-2 augments natural killer cell activity. Nature 291: 335.
5. Charmot D, Ragueneau M, Olive D, Maraninchi D, Mawas C. 1987. Generation of CD8 cytolytic T cells early after autologous or allogeneic hone marrow transplantation. Bone Marrow Transplant. 2: 183.
6. Reittie J E, Gottlieb D, Heslop H E, Leger O, Drexler H G, Hazlehurst G, Hoffbrand A V, Prentice H G, Brenner M K. 1989. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73: 1351.
7. Higuchi C M, Thompson J A, Cox T, Lindgren C G, Buckner C D, Fefer A. 1989. Lymphokine-activated killer function following autologous hone marrow transplantation for refractory hematological malignancies. Cancer Res. 49: 5509.
8. Olive D, Lopez M, Blaise D, Viens P, Stoppa A M, Brandely M, Mawas C, Mannoni P, Maraninchi D. 1991. Cell surface expression of ICAM-1 (CD54) and LFA-3 (CD58), two adhesion molecules, is up-regulated on hone marrow leukemic blasts after in vivo administration of high-dose recombinant interleukin-2. J. Immunother. 10: 412.
9. Blaise D, Olive D, Stoppa A M, Pourreau C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C, Mannoni P, Palmer P, Francks C, Philip T, Maraninchi D. 1990. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous hone marrow transplantation. Blood. 76: 1092.
10. Blaise D, Viens P, Olive D. Stoppa A M, Gabert J, Pourreau C, Attal M, Gaspard M H, Mannoni P, Jasmin C, Palmer P, Francks C, Michel G, Mawas C, Baume D, Philip T, Maraninchi D. 1991. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. Eur: Cytokine Netw. 2:121.
11. Gottlieb D J, Brenner M K, Heslop H E, Bianchi A C, Bello-Fernandez C, Mehta A B, Newland A C, Galazka A R, Scott E M, Hoffbrand A V, Prentice H G. 1989. A phase I clinical trial of recombinant interleukin-2 following high-dose chemoradiotherapy for hematological malignancy: applicability to the elimination of minimal residual disease. Br. J. Cancer 60: 610.
12. Soiffer R J, Murray C, Cochran K, Cameron C, Wang E, Schow P W, Daley J F, Ritz J. 1992. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T cell depleted allogeneic bone marrow transplantation. Blood 79: 517.
13. Vey N, Blaise D, Tiberghien P, Attal M, Pico J L, Reiffers J, Harrousseau J L, Fiere D, Tabilio A, Gabus R, Brandely M, Maraninchi D. 1996. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas. Leuk. Lymphoma 21: 107.
14. Benyunes M C, Higuchi C, York A, Lindgren C, Thompson J A, Buckner C D, Fefer A. 1995. Immunotherapy with interleukin-2 with or without lymphokine-activaled killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant. 16: 283.
15. Blaise D, Stoppa A M, Viens P, Sainty D, Fossat C, Miquel M, Olive D, Bouabdallah R, Gabert J, Baume D, Maraninchi D. 1992. Intensive immunotherapy with recombinant IL-2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections. (Letter) Bone Marrow Transplant. 10: 193.
16. Klempner M S, Noring R, Mier J W, Atkins M B. 1990. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N. Engl. J. Med. 322: 959.
17. Stoppa A M, Fossat C, Blaise D, Viens P, Brandely M, Pourreau C N, Sainty D, Novakovitch G, Miquel M, Juhan-Vague I, Maraninchi D. 1991. Interleukin-2 induces chemotactic deficiency in patients with onco-hematologic malignancies and autologous bone marrow transplantation. Eur. Cytok. Netw. 2: 231.
18. Findley H W Jr. Nasr S, Afify Z, Hnath R, Waldrep K, Ragab A. 1990. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine activated killer cells in vitro. Cancer Invest. 8: 493.
19. Maekawa R, Kitawaga T, Hojo K, Sato K. 1988. Differential efficacies of recombinant murine interferon-gamma and recombinant human interleukin-2 against EL4-bearing mice. J. Interferon Res. 8: 241.
20. Silagi S, Dutkowski R, Schaefer A. 1988. Eradication of mouse melanoma by combined treatment with recombinant interkleukin-2 and recombinant murine interferon-gamma. Int. J. Cancer. 41: 315.
21. Taylor C W, Chase E M, Whitehead R P, Rinehart J J, Neidhart J A, Gonzalez R, Bunn P A, Hersh E M. 1992. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-γ and recombinant interleukin-2 in patients with cancer. J. Immunother. 11: 176.
22. Farace F, Pallardy M, Angevin E, Hercend T, Escudier B, Triebel F. 1994. Metastatic renal-cell carcinoma patients treated with interleukin-2 or interleukin-2 plus interferon-γ: immunological monitoring. Int. J. Cancer 57: 814.
23. Viens P, Blaise D, Stoppa A M, Brandely M, Baume D, Olive D, Resheut M, Delpero J R, Lopez M, Aubert C, Ayme Y, Hans D, Bressac C, Favre R, Maraninchi D. 1992. Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer. J. Immunother. 11: 218.
24. Perussia B, Kobayashi M, Rossi M E, Anegon T, Trinchieri G. 1987. Immune Interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 138: 765.
25. Badaro R, Fallcoff E, Badaro F S, Carvalho E M, Pedral-Sampaio D, Barral A, Carvalho J S, Barral-Netto M, Brandely M, Silva L, Bina J C, Teixeira R, Falcoff R, Rocha H, Ho J L, Johnson W D Jr. 1990. Treatment of visceral leishmaniasis with pentavalent antimony and Interferon gamma. N. Engl. J. Med. 322: 16.
26. Ezekowitz R A, Dinauer M C, Jaffe H S, Orkin S H, Newburger P E. 1988. Partial correction of the phagocytic defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon-gamma. N. Engl. J. Med. 319: 146.
27. Siegel J P, Puri R K. 1991. Interleukin-2 toxicity. (Review) J. Clin. Oncol. 9: 694.
28. Biaise D, Stoppa A M, Olive D, Pico J L, Dreyfus F, Michallet M, Reiffers J, Auzanneau C, Vernant J P, Legros M, Gabus R, Brandely M, Maraninchi D. 1993. Impact of recombinant interleukin-2 after autologous bone marrow transplantation in 44 patients with CRI acute leukemia. Blond 82 (suppl. I): 1136 (abstract).
29. Baumgarten E, Schmid H, Pohl U, Brzoska J, Linderkamp C, Siegert W, Henze G. 1994. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with highrisk acute leukemia. Leukemia 8: 850.